MedTrace Logo

The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis

NCT01033396 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2010-08-17

No results posted yet for this study

Summary

PF-03654764 should reduce the symptoms of allergic rhinitis. In this study patients will be exposed to pollen and their symptoms observed.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

PF-03654764

PF-03654764 single dose 5 mg

DRUG

Allegra

Fexofenadine single dose 60 mg

DRUG

PF-03654764

PF-03654764 single dose 5 mg

DRUG

Allegra-D

Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose

DRUG

Placebo

Placebo single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01033396 on ClinicalTrials.gov